scispace - formally typeset
A

Anja Feldmann

Researcher at Max Planck Society

Publications -  368
Citations -  18932

Anja Feldmann is an academic researcher from Max Planck Society. The author has contributed to research in topics: The Internet & Antigen. The author has an hindex of 67, co-authored 340 publications receiving 17422 citations. Previous affiliations of Anja Feldmann include Saarland University & AT&T.

Papers
More filters
Proceedings Article

Proceedings of the 9th ACM SIGCOMM conference on Internet measurement

TL;DR: This year's IMC paid particular attention to uphold IMC's salient features: the explicit encouragement of publications re-appraising previous findings on new data sets, and the co-existence, in the program, of both full-length and short papers.
Journal ArticleDOI

Retargeting of Human Regulatory T Cells by Single-Chain Bispecific Antibodies

TL;DR: This study provides the first evidence that bispecific Abs can also redirect and activate regulatory T cells against a surface Ag, independently of their TCR specificity.
Patent

System and method for packet network configuration debugging and database

TL;DR: In this article, the authors present a method and system of extracting relevant information from a collection of router configuration files and using the information to populate a data model, which provides a network-wide view of the topology and configuration.
Journal ArticleDOI

Dynamic scheduling on parallel machines

TL;DR: The proof of the lower bound for the two- dimensional mesh actually shows that no greedy-like algorithm can perform well, and the algorithms become less and less greedy as the geometric structure of the network topology becomes more complicated.
Journal ArticleDOI

A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells

TL;DR: A novel unique peptide sequence of ten amino acids as epitope (E-Tag) was incorporated into the binding domains of two novel chimeric antigen receptors (ECARs) directed against either prostate stem cell antigen (PSCA) or CD33 for the treatment of prostate cancer or acute myeloide leukemia (AML).